Kanamycin
File:Kanamycin A.svg | |
Systematic (IUPAC) name | |
---|---|
2-(aminomethyl)- 6-[4,6-diamino-3- [4-amino-3,5-dihydroxy-6-(hydroxymethyl) tetrahydropyran-2-yl]oxy- 2-hydroxy- cyclohexoxy]- tetrahydropyran- 3,4,5-triol | |
Clinical data | |
Pregnancy category |
|
Routes of administration | Oral, intravenous, intramuscular |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | very low after oral delivery |
Metabolism | Unknown |
Biological half-life | 2 hours 30 minutes |
Excretion | Urine (as unchanged drug) |
Identifiers | |
CAS Number | 59-01-8 |
ATC code | A07AA08 (WHO) J01GB04 S01AA24 |
PubChem | CID 6032 |
DrugBank | APRD00026 |
Chemical data | |
Formula | C18H36N4O11 |
Molar mass | 484.499[[Script error: No such module "String".]] |
Kanamycin sulfate is an aminoglycoside antibiotic, available in both oral and intravenous forms, and used to treat a wide variety of infections. Kanamycin is isolated from Streptomyces kanamyceticus[1].
Pharmacology
Kanamycin interacts with the 30S subunit of prokaryotic ribosomes. It induces substantial amounts of mistranslation and indirectly inhibits translocation during protein synthesis[2][3].
Side effects
Serious side effects include tinnitus or loss of hearing, toxicity to kidneys, and allergic reactions to the drug.[4]
Use in research
Kanamycin is used in molecular biology as a selective agent most commonly to isolate bacteria (e.g., E. coli) which have taken up genes (e.g., of plasmids) coupled to a gene coding for kanamycin resistance (primarily Neomycin phosphotransferase II [NPT II/Neo]). Bacteria that have been transformed with a plasmid containing the kanamycin resistance gene are plated on kanamycin (50-100ug/ml) containing agar plates or are grown in media containing kanamycin (50-100ug/ml). Only the bacteria that have successfully taken up the kanamycin resistance gene become resistant and will grow under these conditions. As a powder kanamycin is white to off-white and is soluble in water (50mg/ml).
Mammalian cells and other eukaryotes are screened using G418, a similar aminoglycoside antibiotic, which KanMX confers resistance against.
At least one such gene, Atwbc19[5] is native to a plant species, of comparatively large size and its coded protein acts in a manner which decreases the possibility of Horizontal Gene Transfer from the plant to bacteria; it may be incapable of giving resistance to kanamycin to bacteria even if gene transfer occurs.
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
ar:كاناميسين de:Kanamycine es:Kanamicina fr:Kanamycine it:Kanamicina ja:カナマイシン pl:Kanamycyna pt:Canamicina ru:Канамицин sl:Kanamicin sr:Kanamicin th:กานามัยซิน
zh:卡纳霉素- ↑ Garrod, L.P., et al.: "Antibiotic and Chemotherapy", page 131. Churchill Livingstone, 1981
- ↑ Pestka, S.: "The Use of Inhibitors in Studies on Protein Synthesis", Methods in Enzymology 30, pp.261-282, 1975
- ↑ Misumi, M. & Tanaka, N.: "Mechanism of Inhibition of Translocation by Kanamycin and Viomycin: A Comparative Study with Fusidic Acid, Biochem.Biophys.Res.Commun. 92, pp.647-654, 1980
- ↑ Consumer Drug Information: Kanamycin, 2 April 2008, retrieved 2008-05-04
- ↑ Horizontal Gene Transfer: Plant vs. Bacterial Genes for Antibiotic Resistance Scenario's—What's the Difference?
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- 2Fix
- Aminoglycoside antibiotics
- World Health Organization essential medicines